Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...

Maturity-onset diabetes of the young (MODY) is an autosomal dominant monogenic form of diabetes. This report describes a case with hepatocyte nuclear factor 1-alpha ( HNF1A )-MODY due to a novel ...

A novel vaccine targeting triple-negative breast cancer (TNBC), one of the most aggressive and hard-to-treat forms, has shown ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Experts at SICP 2025 outline how molecular mechanisms and bedside assessments can guide personalised treatment for ...

A new vaccine targeting triple-negative breast cancer (TNBC), one of the most hard-to-treat types, has shown early promise in ...

Based on the response data, coupled with the supportive IFN- <GAMMA> biomarker data, Pliant plans to accelerate the development of PLN-101095 with the initiation of a Phase 1b indication expansion ...

Medicenna Therapeutics (MDNAF) presented updated clinical data from the ongoing Phase 1/2 ABILITY-1 study evaluating MDNA11 in patients with ...